RCAMU
RVNC

Rothschild & Co Asset Management US’s Revance Therapeutics, Inc. RVNC Stock Holding History

Rothschild & Co Asset Management US’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$6.82M Buy
369,648
+154,713
+72% +$3.54M 0.1% 151
2022
Q3 		$5.8M Sell
214,935
-1,535
-0.7% -$31.1K 0.1% 159
2022
Q2 		$2.99M Sell
216,470
-5,938
-3% -$91.4K 0.05% 220
2022
Q1 		$4.34M Sell
222,408
-66,716
-23% -$1.01M 0.06% 217
2021
Q4 		$4.72M Sell
289,124
-15,148
-5% -$253K 0.06% 223
2021
Q3 		$8.48M Sell
304,272
-40,759
-12% -$1.16M 0.11% 193
2021
Q2 		$10.2M Sell
345,031
-38,797
-10% -$1.12M 0.12% 184
2021
Q1 		$10.7M Sell
383,828
-46,008
-11% -$1.27M 0.13% 188
2020
Q4 		$12.2M Sell
429,836
-8,485
-2% -$220K 0.16% 176
2020
Q3 		$11M Sell
438,321
-45,255
-9% -$1.19M 0.2% 184
2020
Q2 		$11.8M Buy
483,576
+3,209
+0.7% +$63.3K 0.17% 200
2020
Q1 		$7.11M Sell
480,367
-79,397
-14% -$1.64M 0.11% 228
2019
Q4 		$9.09M Buy
559,764
+524,707
+1,497% +$8.14M 0.09% 257
2019
Q3 		$456K Buy
35,057
+7,636
+28% +$93.4K ﹤0.01% 340
2019
Q2 		$356K Sell
27,421
-291
-1% -$3.67K ﹤0.01% 344
2019
Q1 		$437K Sell
27,712
-21,729
-44% -$377K ﹤0.01% 354
2018
Q4 		$995K Buy
49,441
+590
+1% +$13K 0.01% 352
2018
Q3 		$1.21M Buy
48,851
+7,299
+18% +$199K 0.01% 354
2018
Q2 		$1.14M Sell
41,552
-2,926
-7% -$87.9K 0.01% 354
2018
Q1 		$1.37M Sell
44,478
-4,823
-10% -$155K 0.02% 334
2017
Q4 		$1.76M Sell
49,301
-3,707
-7% -$106K 0.02% 325
2017
Q3 		$1.46M Sell
53,008
-1,158
-2% -$28.1K 0.02% 317
2017
Q2 		$1.43M Sell
54,166
-2,444
-4% -$54.5K 0.02% 351
2017
Q1 		$1.18M Sell
56,610
-4,176
-7% -$85.8K 0.01% 359
2016
Q4 		$1.26M Buy
60,786
+49,978
+462% +$837K 0.02% 373
2016
Q3 		$175K Buy
10,808
+269
+3% +$3.91K ﹤0.01% 527
2016
Q2 		$143K Buy
+10,539
New +$186K ﹤0.01% 557

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Rothschild & Co Asset Management US's RVNC Position: Q4 2022 in Review

Rothschild & Co Asset Management US increased its Revance Therapeutics, Inc. (RVNC) stake by 72% in Q4 2022, buying an estimated $3.54M and bringing the position to 369,648 shares worth $6.82M. The position accounts for 0.1% of the portfolio, ranked #151.

Rothschild & Co Asset Management US first reported a position in RVNC in Q2 2016 and has held it in 27 quarters since. The position peaked at $12.2M in Q4 2020. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2022.

  • Rothschild & Co Asset Management US held 369,648 shares of Revance Therapeutics, Inc. worth $6.82M as of Q4 2022.
  • Rothschild & Co Asset Management US bought 154,713 Revance Therapeutics, Inc. shares in Q4 2022, an estimated $3.54M.
  • Revance Therapeutics, Inc. made up 0.1% of Rothschild & Co Asset Management US's portfolio in Q4 2022, its #151 holding.
  • Rothschild & Co Asset Management US first reported a position in Revance Therapeutics, Inc. in Q2 2016 and has held it in 27 quarters since.
  • Rothschild & Co Asset Management US's Revance Therapeutics, Inc. position peaked at $12.2M in Q4 2020.
  • 193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2022.

Based on Rothschild & Co Asset Management US's 13F filing for Q4 2022, filed 14 Feb 2023.